Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phosphoaminophosphonic acid guanylate ester is a synthetic, non-hydrolyzable analog of guanosine triphosphate (GTP), in which the oxygen atom bridging the beta and gamma phosphate groups is replaced by a nitrogen atom. This modification confers resistance to hydrolysis, making it useful as a biochemical tool for studying G-protein signaling pathways. The compound binds tightly to G-proteins in the presence of magnesium ions and acts as a potent stimulator of adenylate cyclase, leading to increased cyclic AMP production. It is primarily used in research settings to investigate mechanisms involving GTP-binding proteins and signal transduction processes[1][2][3][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phosphoaminophosphonic acid guanylate ester.